Good distribution practice picks up the moment a finished product leaves manufacturing and follows it through every warehouse, vehicle, and handoff until it reaches a pharmacy, hospital, or clinical site. The European Union codified this in its 2013 GDP guidelines, and the World Health Organization (WHO) maintains a parallel standard, part of a broader convergence around common good distribution practices frameworks worldwide. The United States enforces the same intent through a different structure: rather than a single FDA “GDP rule,” requirements are layered across the Drug Supply Chain Security Act (DSCSA), 21 CFR Part 203, FDA’s prescription drug marketing regulation, and state wholesale distributor licensing. A partner operating internationally has to satisfy all three at once.
Current Good Manufacturing Practice (cGMP) governs the production of a drug: the facility, equipment, and testing that confirm a batch meets its specification. Good distribution practice picks up after that batch is released, governing storage conditions, transport validation, chain of custody, and the paper trail proving nothing changed in transit. The two frameworks share a philosophy, documented procedures, traceable records, but they answer different questions. cGMP asks whether a product was made correctly; good distribution practice asks whether it stayed correct after it left the plant. A facility can hold flawless cGMP certifications and still fail a distribution audit if its trucks, lanes, or handoffs are not under the same discipline.
A good distribution practice program is not one control. It is a set of five interlocking requirements, and a gap in any one of them puts the whole chain at risk.
Every good distribution practice program runs under a documented quality system, overseen by a named responsible person who owns deviations, complaints, and corrective and preventive action, or CAPA. Auditors expect that person to show live records, not policy documents written to pass inspection. Eagle Life Science signs a formal quality agreement with every partner in its vetted network, assigning responsibility before a shipment ever moves.
Storage facilities must be qualified, monitored, and mapped to the temperature range each product requires, most commonly 2°C to 8°C for refrigerated biologics. Eagle’s cold chain compliance runs on continuous monitoring across that full range inside a 65,000-square-foot U.S. customs-bonded warehouse, so temperature data exists for every minute a product sits in storage, not just at intake and release.
Good distribution practice extends the same rigor to the road. Lanes must be validated for the routes and seasons a shipment actually travels, and vehicles need qualified packaging or active temperature control. Eagle pairs Eupry sensor data with Samsara fleet visibility, so a shipment’s location and temperature are verifiable in one record, not reconciled after delivery.
Every requirement above is only as strong as the paper trail behind it. Documentation standards call for records created at the moment each step happens, not reconstructed from memory when an audit is scheduled. Eagle’s clinical trial kitting work applies this same standard down to the component level, tracing each vial or label back to its lot and handling history.
Good distribution practice also governs what happens when a product needs to come back. Returned goods must be quarantined and assessed before re-entering salable stock, recall procedures must reach every point in the chain within a defined window, and receiving processes must screen for falsified or diverted product. A program covering only outbound shipments has covered half of good distribution practice.
GDP certification tells a buyer that a third party has independently verified a logistics provider’s quality system, not just accepted a self-reported claim. But certification alone does not tell the whole story: a certified broker and a certified operator can hold the same paperwork while running very different operations. A broker books freight and hands it to subcontractors it does not fully control, and its certificate says nothing about whether every sub-vendor in its chain carries the same certification.
GDP pharma compliance gets tested at every customs checkpoint, hospital receiving dock, and DSCSA audit, not just at initial certification. Eagle Life Science runs its GDP-certified quality system on owned assets: a customs-bonded, temperature-monitored facility less than two miles from Boston Logan International Airport, paired with secure transport certified under TAPA (the Transported Asset Protection Association) and cGMP-aligned pharmaceutical quality assurance. Every partner in Eagle’s vetted network operates under a signed quality agreement, so the standard a shipper signs up for at intake is the same one that holds through cGMP warehousing and last-mile delivery.
A GDP-certified quality system only proves itself when every partner in the chain operates under the same standard.
Most good distribution practice failures do not show up as a missing certificate. They show up in the operational details behind it: weak sub-vendor qualification, where a certified provider cannot produce records showing how it vetted its own carriers and warehouses; temperature excursions on the last mile, where monitoring tracks conditions inside a facility but loses visibility at final delivery; and deviation records that appear only after an audit is scheduled instead of when the issue occurred. Our breakdown of what QA directors find when they audit logistics partners covers these patterns in more detail.
A good distribution practice program cannot stop at the warehouse door, and it cannot start only once a truck leaves the dock. The standard treats storage and transport as one continuous chain, so a product held at validated conditions and then handed to a carrier without the same discipline has met only half of it. The seam between vendors, where a warehouse operator and a transportation provider are separate companies, is the highest-risk point: each documents its own leg well, but the handoff between them is where records go thin. A shipment moving through commercial distribution under one operator keeps that seam from opening.
What is good distribution practice in pharmaceutical logistics?
The set of standards governing how pharmaceutical products are stored, handled, and transported after manufacturing, from temperature-controlled storage to chain-of-custody documentation in transit.
Is GDP the same as GMP?
No. cGMP governs how a drug is manufactured; good distribution practice governs what happens to it after, during storage and distribution.
Who enforces GDP compliance in the United States?
The US has no single GDP regulation. Requirements are enforced through the Drug Supply Chain Security Act, 21 CFR Part 203, and state wholesale distributor licensing.
Does good distribution practice apply to both warehousing and transportation?
Yes. Storage and transport are treated as one continuous chain, so the same temperature and documentation controls apply through delivery, not just in the warehouse.
What documentation does a GDP-compliant shipment require?
Records showing who handled a shipment, when, and under what conditions at every step, created as the work happens, plus a documented chain of custody through each handoff.
What happens when a temperature-sensitive shipment breaks its required range?
The deviation must be logged immediately, investigated, and resolved through a documented CAPA process, with the responsible party identified rather than left ambiguous.
How can a company verify that a logistics partner is truly GDP certified?
Ask for more than the certificate. Request evidence of sub-vendor qualification, a sample deviation record with its CAPA, and proof certification extends to every partner touching the shipment.
A good distribution practice program is only as strong as its weakest handoff, and the surest way to remove that weak point is to reduce the number of handoffs in the first place. Eagle Life Science runs storage, transportation, and documentation under one GDP-certified quality system, just minutes from Boston Logan International Airport, so the standard a shipment starts under is the standard it finishes under. Tell Eagle’s team what you ship and what your auditors expect to see.
https://www.eagle-freight.com/wp-content/uploads/2026/06/Laboratory-Sample-Logistics-in-Boston-The-Chain-of-Custody-Gap-Most-Organizations-Miss-at-Logan.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-06-16 10:27:042026-06-16 10:28:35Laboratory Sample Logistics in Boston: The Chain-of-Custody Gap Most Organizations Miss at Logan https://www.eagle-freight.com/wp-content/uploads/2026/06/Pharmaceutical-Last-Mile-Delivery-In-a-Pull-Model-Supply-Chain-Its-the-Only-Leg-That-Cant-Fail.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-06-16 10:12:002026-06-16 10:12:03Pharmaceutical Last Mile Delivery: In a Pull-Model Supply Chain, It’s the Only Leg That Can’t Fail https://www.eagle-freight.com/wp-content/uploads/2026/06/The-process-of-loading-medical-ampoules-for-vaccines-onto-a-conveyor_.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-06-16 08:35:242026-06-16 08:35:26Why CDMOs Are Debating Freight Mode When Pharmaceutical Importer of Record Liability Is the Real Risk https://www.eagle-freight.com/wp-content/uploads/2026/02/Dry-Ice-Replenishment-In-Bond.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2026-02-27 15:46:322026-04-24 11:12:49How Dry Ice Shipping in Bond Protects Pharmaceutical Shipments https://www.eagle-freight.com/wp-content/uploads/2025/12/How-Cold-Chain-Logistics-Ensures-Pharmaceutical-Safety.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2025-12-22 10:01:342026-04-24 16:56:17How Cold Chain Pharmaceutical Logistics Ensures Product Integrity & Patient Safety https://www.eagle-freight.com/wp-content/uploads/2025/12/How-Cold-Chain-Logistics-Safeguards-Pharmaceutical-Integrity.jpg 1250 2000 Abstrakt Marketing /wp-content/uploads/2025/08/EagleHeader-1.png Abstrakt Marketing2025-12-18 12:29:442026-04-24 11:12:50How to Evaluate a Cold Chain Logistics Provider for Pharmaceutical Shipments